These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1281 related items for PubMed ID: 29246130

  • 1. Enteral vitamin A for reducing severity of bronchopulmonary dysplasia in extremely preterm infants: a randomised controlled trial.
    Rakshasbhuvankar A, Patole S, Simmer K, Pillow JJ.
    BMC Pediatr; 2017 Dec 16; 17(1):204. PubMed ID: 29246130
    [Abstract] [Full Text] [Related]

  • 2. Enteral Vitamin A for Reducing Severity of Bronchopulmonary Dysplasia: A Randomized Trial.
    Rakshasbhuvankar AA, Simmer K, Patole SK, Stoecklin B, Nathan EA, Clarke MW, Pillow JJ.
    Pediatrics; 2021 Jan 16; 147(1):. PubMed ID: 33386338
    [Abstract] [Full Text] [Related]

  • 3. Early postnatal high-dose fat-soluble enteral vitamin A supplementation for moderate or severe bronchopulmonary dysplasia or death in extremely low birthweight infants (NeoVitaA): a multicentre, randomised, parallel-group, double-blind, placebo-controlled, investigator-initiated phase 3 trial.
    Meyer S, Bay J, Franz AR, Ehrhardt H, Klein L, Petzinger J, Binder C, Kirschenhofer S, Stein A, Hüning B, Heep A, Cloppenburg E, Muyimbwa J, Ott T, Sandkötter J, Teig N, Wiegand S, Schroth M, Kick A, Wurm D, Gebauer C, Linnemann K, Kittel J, Wieg C, Kiechl-Kohlendorfer U, Schmidt S, Böttger R, Thomas W, Brevis Nunez F, Stockmann A, Kriebel T, Müller A, Klotz D, Morhart P, Nohr D, Biesalski HK, Giannopoulou EZ, Hilt S, Poryo M, Wagenpfeil S, Haiden N, Ruckes C, Ehrlich A, Gortner L, NeoVitaA trial investigators.
    Lancet Respir Med; 2024 Jul 16; 12(7):544-555. PubMed ID: 38643780
    [Abstract] [Full Text] [Related]

  • 4. Early postnatal additional high-dose oral vitamin A supplementation versus placebo for 28 days for preventing bronchopulmonary dysplasia or death in extremely low birth weight infants.
    Meyer S, Gortner L, NeoVitaA Trial Investigators.
    Neonatology; 2014 Jul 16; 105(3):182-8. PubMed ID: 24434948
    [Abstract] [Full Text] [Related]

  • 5. The N3RO trial: a randomised controlled trial of docosahexaenoic acid to reduce bronchopulmonary dysplasia in preterm infants < 29 weeks' gestation.
    Collins CT, Gibson RA, Makrides M, McPhee AJ, Sullivan TR, Davis PG, Thio M, Simmer K, Rajadurai VS, N3RO Investigative Team.
    BMC Pediatr; 2016 Jun 01; 16():72. PubMed ID: 27250120
    [Abstract] [Full Text] [Related]

  • 6. Intratracheal budesonide mixed with surfactant to increase survival free of bronchopulmonary dysplasia in extremely preterm infants: statistical analysis plan for the international, multicenter, randomized PLUSS trial.
    Francis KL, McKinlay CJD, Kamlin COF, Cheong JLY, Dargaville PA, Dawson JA, Doyle LW, Jacobs SE, Davis PG, Donath SM, Manley BJ.
    Trials; 2023 Nov 06; 24(1):709. PubMed ID: 37932774
    [Abstract] [Full Text] [Related]

  • 7. Intratracheal budesonide mixed with surfactant to increase survival free of bronchopulmonary dysplasia in extremely preterm infants: study protocol for the international, multicenter, randomized PLUSS trial.
    Manley BJ, Kamlin COF, Donath S, Huang L, Birch P, Cheong JLY, Dargaville PA, Dawson JA, Doyle LW, Jacobs SE, Wilson R, Davis PG, McKinlay CJD.
    Trials; 2023 May 09; 24(1):320. PubMed ID: 37161488
    [Abstract] [Full Text] [Related]

  • 8. Effect of Inhaled Nitric Oxide on Survival Without Bronchopulmonary Dysplasia in Preterm Infants: A Randomized Clinical Trial.
    Hasan SU, Potenziano J, Konduri GG, Perez JA, Van Meurs KP, Walker MW, Yoder BA, Newborns Treated With Nitric Oxide (NEWNO) Trial Group.
    JAMA Pediatr; 2017 Nov 01; 171(11):1081-1089. PubMed ID: 28973344
    [Abstract] [Full Text] [Related]

  • 9. Effect of Hydrocortisone Therapy Initiated 7 to 14 Days After Birth on Mortality or Bronchopulmonary Dysplasia Among Very Preterm Infants Receiving Mechanical Ventilation: A Randomized Clinical Trial.
    Onland W, Cools F, Kroon A, Rademaker K, Merkus MP, Dijk PH, van Straaten HL, Te Pas AB, Mohns T, Bruneel E, van Heijst AF, Kramer BW, Debeer A, Zonnenberg I, Marechal Y, Blom H, Plaskie K, Offringa M, van Kaam AH, STOP-BPD Study Group.
    JAMA; 2019 Jan 29; 321(4):354-363. PubMed ID: 30694322
    [Abstract] [Full Text] [Related]

  • 10. Randomized controlled trial of enteral vitamin D supplementation (ViDES) in infants <28 weeks gestational age or <1000 g birth weight: study protocol.
    Romero-Lopez M, Tyson JE, Naik M, Pedroza C, Holzapfel LF, Avritscher E, Mosquera R, Khan A, Rysavy M.
    Trials; 2024 Jun 28; 25(1):423. PubMed ID: 38943179
    [Abstract] [Full Text] [Related]

  • 11. Effect of Enteral Vitamin A on Fecal Calprotectin in Extremely Preterm Infants: A Nested Prospective Observational Study.
    Rakshasbhuvankar AA, Pillow JJ, Patole SK, Nathan EA, Simmer K.
    Neonatology; 2021 Jun 28; 118(6):720-726. PubMed ID: 34518481
    [Abstract] [Full Text] [Related]

  • 12. A randomized controlled trial protocol comparing the feeds of fresh versus frozen mother's own milk for preterm infants in the NICU.
    Sun H, Cao Y, Han S, Cheng R, Liu L, Liu J, Xia S, Zhang J, Li Z, Cheng X, Yang C, Pan X, Li L, Ding X, Wang R, Wu M, Li X, Shi L, Xu F, Yu F, Pan J, Zhang X, Li L, Yang J, Li M, Yan C, Zhou Q, Lu J, Wei M, Wang L, Yang L, Ye XY, Unger S, Kakulas F, Lee SK.
    Trials; 2020 Feb 11; 21(1):170. PubMed ID: 32046760
    [Abstract] [Full Text] [Related]

  • 13. Validation of the National Institutes of Health consensus definition of bronchopulmonary dysplasia.
    Ehrenkranz RA, Walsh MC, Vohr BR, Jobe AH, Wright LL, Fanaroff AA, Wrage LA, Poole K, National Institutes of Child Health and Human Development Neonatal Research Network.
    Pediatrics; 2005 Dec 11; 116(6):1353-60. PubMed ID: 16322158
    [Abstract] [Full Text] [Related]

  • 14. Up-date on the NeoVitaA Trial: Obstacles, challenges, perspectives, and local experiences.
    Meyer S, Gortner L, NeoVitaA Trial investigators.
    Wien Med Wochenschr; 2017 Sep 11; 167(11-12):264-270. PubMed ID: 27671007
    [Abstract] [Full Text] [Related]

  • 15. Pulmonary Gas Exchange Improves over the First Year in Preterm Infants with and without Bronchopulmonary Dysplasia.
    Choi YJ, Stoecklin B, Hemy NR, Hall GL, Doherty DA, Simpson SJ, Pillow JJ.
    Neonatology; 2021 Sep 11; 118(1):98-105. PubMed ID: 33592606
    [Abstract] [Full Text] [Related]

  • 16. Effect of early low-dose hydrocortisone on survival without bronchopulmonary dysplasia in extremely preterm infants (PREMILOC): a double-blind, placebo-controlled, multicentre, randomised trial.
    Baud O, Maury L, Lebail F, Ramful D, El Moussawi F, Nicaise C, Zupan-Simunek V, Coursol A, Beuchée A, Bolot P, Andrini P, Mohamed D, Alberti C, PREMILOC trial study group.
    Lancet; 2016 Apr 30; 387(10030):1827-36. PubMed ID: 26916176
    [Abstract] [Full Text] [Related]

  • 17. Using Measurements of Shunt and Ventilation-to-Perfusion Ratio to Quantify the Severity of Bronchopulmonary Dysplasia.
    Dassios T, Curley A, Morley C, Ross-Russell R.
    Neonatology; 2015 Apr 30; 107(4):283-8. PubMed ID: 25766074
    [Abstract] [Full Text] [Related]

  • 18. Safety and Efficacy of Early Vitamin D Supplementation in Critically Ill Extremely Preterm Infants: An Ancillary Study of a Randomized Trial.
    Aristizabal N, Holder MP, Durham L, Ashraf AP, Taylor S, Salas AA.
    J Acad Nutr Diet; 2023 Jan 30; 123(1):87-94. PubMed ID: 35728797
    [Abstract] [Full Text] [Related]

  • 19. Ibuprofen use to reduce the incidence and severity of bronchopulmonary dysplasia: a pilot study.
    Raju NV, Bharadwaj RA, Thomas R, Konduri GG.
    J Perinatol; 2000 Jan 30; 20(1):13-6. PubMed ID: 10693094
    [Abstract] [Full Text] [Related]

  • 20. Vitamin D and bronchopulmonary dysplasia in preterm infants.
    Joung KE, Burris HH, Van Marter LJ, McElrath TF, Michael Z, Tabatabai P, Litonjua AA, Weiss ST, Christou H.
    J Perinatol; 2016 Oct 30; 36(10):878-82. PubMed ID: 27467562
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 65.